Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8975 results

  1. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  2. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

    Awaiting development Reference number: GID-TA11773 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  3. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  6. Percutaneous transluminal renal sympathetic denervation for resistant hypertension

    Awaiting development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  9. Artificial intelligence (AI)-derived software to help clinical decision making in stroke

    Awaiting development Reference number: GID-HTG10529 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    In development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  13. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 14 April 2026.

    Technology appraisal guidance
    In consultation

  14. Bepirovirsen for treating chronic hepatitis B [ID6608]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 7 April 2026.

    Technology appraisal guidance
    In consultation

  15. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development